The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
Open accessAbstract
The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-A resolution, both with and without an EGFRK-specific inhibitor currently in Phase III clinical trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva(TM)). The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains. Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor. Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain. Significant intermolecular contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citationCell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Hunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Improved Fourier coefficients for maps using phases from partial structures with errors
Read, R. J. (1986) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767386099622 · Cited by 1,873
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Growth factor signaling by receptor tyrosine kinases
Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,430
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Protein Tyrosine Kinase Structure and Function
Hubbard, S. R., & Till, J. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.373 · Cited by 1,171
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Hubbard, S. R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5572 · Cited by 953
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 643
Self-citationSmart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation
Yamaguchi, H., & Hendrickson, W. A. (1996) · Nature · doi:10.1038/384484a0 · Cited by 492
Practical Protein Crystallography
(1999) · Elsevier eBooks · doi:10.1016/b978-0-12-486052-0.x5000-3 · Cited by 488
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447
Ligand-Induced Transformation by a Noninternalizing Epidermal Growth Factor Receptor
Wells, A., Welsh, J. B., Lazar, C. S., Wiley, H. S., Gill, G. N., & Rosenfeld, M. G. (1990) · Science · doi:10.1126/science.2305263 · Cited by 411
Binding specificities and affinities of egf domains for ErbB receptors
Jones, J. T., Akita, R. W., & Sliwkowski, M. X. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00283-5 · Cited by 381
Self-citationStructure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism
Mohammadi, M., Schlessinger, J., & Hubbard, S. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80131-2 · Cited by 370
Chen, W. S., Lazar, C. S., Lund, K. A., Welsh, J. B., Chang, C.-P., Walton, G. M., Der, C. J., Wiley, H. S., Gill, G. N., & Rosenfeld, M. G. (1989) · Cell · doi:10.1016/0092-8674(89)90867-2 · Cited by 350
Moriki, T., Maruyama, H., & Maruyama, I. N. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4923 · Cited by 337
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
EGF receptor in neoplasia and metastasis
Khazaie, K., Schirrmacher, V., & Lichtner, R. B. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665957 · Cited by 288
Rewcastle, G. W., Denny, W. A., Bridges, A. J., Zhou, H., Cody, D. R., McMichael, A., & Fry, D. W. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a008 · Cited by 263
Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233
Wissner, A., Berger, D. M., Boschelli, D. H., Floyd, M. B., Greenberger, L. M., Gruber, B. C., Johnson, B. D., Mamuya, N., Nilakantan, R., Reich, M. F., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000206a · Cited by 207
Crystal structure of casein kinase-1, a phosphate-directed protein kinase.
Xu, R. M., Carmel, G., Sweet, R. M., Kuret, J., & Cheng, X. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07082.x · Cited by 193
Structure of the Carboxyl-terminal Src Kinase, Csk
Ogawa, A., Takayama, Y., Sakai, H., Chong, K. T., Takeuchi, S., Nakagawa, A., Nada, S., Okada, M., & Tomitake Tsukihara, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200086200 · Cited by 152
Owen, D., Noble, M., Garman, E. F., Papageorigiou, A., & Johnson, L. (1995) · Structure · doi:10.1016/s0969-2126(01)00180-0 · Cited by 148
Gotoh, N., Tojo, A., Hino, M., Yazaki, Y., & Shibuya, M. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90812-y · Cited by 126
ATP site-directed competitive and irreversible inhibitors of protein kinases
Garc�a-Echeverr�a, C., Traxler, P. M., & Evans, D. B. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<28::aid-med2>3.0.co;2-2 · Cited by 124
Palmer, B. D., Trumpp-Kallmeyer, S., Fry, D. W., Nelson, J. M., Showalter, H. D. H., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960789h · Cited by 115
Giant protein kinases: domain interactions and structural basis of autoregulation.
Kobe, B., Heierhorst, J., Feil, S. C., Parker, M. W., Benian, G. M., Weiss, K. R., & Kemp, B. E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01072.x · Cited by 106
Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
Kelloff, G. J., Fay, J. R., Steele, V. E., Lubet, R., Boone, C. W., Crowell, J. A., & Sigman, C. C. (1996) · PubMed · Cited by 96
Penuel, E. M., Akita, R. W., & Sliwkowski, M. X. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202510200 · Cited by 78
Self-citationChantry, A. (1995) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82892-7 · Cited by 74
Basu, M., Sen-Majumdar, A., Basu, A., Murthy, U., & Das, M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67174-1 · Cited by 42
Schaefer, G., Akita, R. W., & Sliwkowski, M. X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.859 · Cited by 35
Self-citationTimms, J. F., Noble, M. E. M., & Gregoriou, M. (1995) · Biochemical Journal · doi:10.1042/bj3080219 · Cited by 7
Cited by
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
“From analysis of the crystal structure of the EGFR kinase domain bound to erlotinib, it is has been shown that the wild-type threonine residue at position 790 is located in the hydrophobic ATP-binding pocket of the catalytic region, where it forms a critical hydrogen bond with the drug [”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Metadata
- Authors
- Stamos, J., Sliwkowski, M. X., & Eigenbrot, C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 277
- Issue
- 48
- Pages
- 46265-46272
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2133051701
- Cited by
- 1,574
- References
- 47
- FWCI
- 15.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.